stocks logo

EKSO Earnings

Ekso Bionics Holdings Inc
$
2.980
-0.01(-0.334%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings

Earning Analysis

Welcome to our in-depth analysis of Ekso Bionics Holdings Inc(EKSO) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Ekso Bionics Holdings Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.

Earnings Forecast

Revenue
EPS
Currency: USD
Actual
Estimate

Surprise Analysis

Name
EPS
Revenue
Price Reaction
Fiscal QuarterEarning DateTimeEstimateActualSurprise%EstimateActualSurprise%1D5D
FY2025Q22025-07-28After Hours-1.20-1.24-3.334.31M2.06M-52.30-27.37-22.96
FY2025Q12025-05-05After Hours-0.11-0.12-9.094.62M3.38M-27.02-9.11-10.39
FY2024Q42025-03-03After Hours-0.06-0.14-133.335.05M5.09M+0.79-1.22-27.40
FY2024Q32024-10-28After Hours-0.08-0.10-25.005.55M4.13M-25.62-15.04-22.92
FY2024Q22024-07-29--0.11-0.13-18.185.17M4.95M-4.27+14.23-23.08
FY2024Q12024-04-29--0.16-0.20-25.004.99M3.76M-24.77+3.20+4.80
FY2023Q42024-03-04--0.11-0.22-100.004.77M4.85M+1.55+5.53-22.61
FY2023Q32023-10-26--0.31-0.24+22.584.53M4.61M+1.74-6.25+62.50
FY2023Q22023-07-27--0.28-0.31-10.714.35M4.70M+8.11-4.80-5.60
-2023-04-27--0.31-0.33-6.45---+2.86+6.43

EKSO Earnings Analysis

Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Ekso Bionics Holdings Inc reported performance for FY2025Q2, announced on 2025-07-28. The company achieved an EPS of -1.24, compared to analyst estimates of -1.20 by -3.33% . Revenue for the quarter reached 2.06M compared to expectations of 4.31M by -52.30% .
The stock price reacted with a -27.37% one-day change and a -22.96% five-day change following the earnings release. These movements reflect market reaction in Ekso Bionics Holdings Inc growth trajectory and strategic initiatives.

EKSO Earnings Forecast

Looking ahead, Ekso Bionics Holdings Inc(EKSO) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q3 project quarter revenue of 4.40M and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been No Change by 0%. For the upcoming , revenue estimates have been adjusted Go Down by -53.80% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Ekso Bionics Holdings Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

Estimate Revision

The chart shows the correlation between EKSO's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Revenue Estimates for Q3 2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-53.80%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
--
Revenue Estimate-Annual FY 2025:15.00M
--
EPS Estimate-Annual FY 2025:0
Stock Price2.98

EKSO Revenue and EPS Performance: A Historical Perspective

Ekso Bionics Holdings Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-07-28,After Hours):
EPS: -1.24 (Actual) vs.-1.20 (Estimate) (-3.33%)
Revenue: 2.06M (Actual) vs. 4.31M (Estimate) (-52.30%)
Price Reaction: -27.37%(1-Day), -22.96%(5-Day)
FY2025Q1 (2025-05-05,After Hours):
EPS: -0.12 (Actual) vs.-0.11 (Estimate) (-9.09%)
Revenue: 3.38M (Actual) vs. 4.62M (Estimate) (-27.02%)
Price Reaction: -9.11%(1-Day), -10.39%(5-Day)
FY2024Q4 (2025-03-03,After Hours):
EPS: -0.14 (Actual) vs.-0.06 (Estimate) (-133.33%)
Revenue: 5.09M (Actual) vs. 5.05M (Estimate) (0.79%)
Price Reaction: -1.22%(1-Day), -27.40%(5-Day)
Earnings Reaction
The chart below shows how EKSO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, EKSO sees a +0.26% change in stock price 10 days leading up to the earnings, and a -7.39% change 10 days following the report. On the earnings day itself, the stock moves by +0.78%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed -27.37% on the day following the earnings release and then changed by -34.22% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.

Transcript Summary

Ekso Bionics Holdings Inc (EKSO) Q2 2025 Earnings Call Summary
Negative
2025-07-28
The earnings call highlighted several negative factors: a significant revenue decline, reduced gross profit and margins, and an increased net loss. The Q&A revealed deferred sales due to regulatory issues and uncertainty in Enterprise Health sales recovery. Despite some progress in the Indego Personal business and cost management efforts, the challenges in coding, coverage, and payment processes, alongside supply chain risks and AI integration uncertainties, contribute to a negative sentiment. The lack of clear guidance on grant reliance further exacerbates concerns, likely leading to a negative stock price reaction.
Ekso Bionics Holdings Inc (EKSO) Q1 2025 Earnings Call Summary
Neutral
2025-05-05
The earnings call presents a mixed picture: while there are positive developments such as improved cash position, strong gross margins, and strategic partnerships, there are also concerns about revenue decline, macroeconomic uncertainties, and reliance on enterprise health. The Q&A section did not alleviate these concerns, with management unable to provide clear guidance on certain issues. The lack of a share repurchase program further tempers positive sentiment. Given these factors, the likely stock price movement is neutral, within the -2% to 2% range over the next two weeks.
Ekso Bionics Holdings Inc (EKSO) Q4 2024 Earnings Call Summary
Neutral
2025-03-04
The earnings call presents a mixed outlook. Positive aspects include improved gross margins and reduced operating expenses, along with optimistic guidance for multi-unit orders in North America. However, the company missed EPS expectations and faces regulatory and market access challenges, which could temper investor enthusiasm. The lack of a share repurchase program and unclear timelines for private payer engagement further contribute to a neutral sentiment. The company's financial performance shows slight improvement, but not enough to strongly impact the stock price positively or negatively.
Ekso Bionics Holdings Inc (EKSO) Q4 2024 Earnings Call Summary
Neutral
2025-03-03
The earnings call presents mixed signals: improved financial metrics, optimistic guidance, and expanding market presence are positive, but offset by regulatory uncertainties, competitive pressures, and supply chain risks. The lack of a share repurchase program and unclear management responses in the Q&A session further contribute to a cautious outlook. With no new partnerships or strong catalysts, the stock is likely to remain stable, resulting in a neutral sentiment.
Ekso Bionics Holdings, Inc. (EKSO) Q3 2024 Earnings Call Summary
Negative
2024-10-28
The earnings call highlights several concerns: decreased quarterly sales, supply chain disruptions, regulatory and competitive pressures, and a public offering. Despite improvements in net loss and gross margins, the weak financial performance and uncertainties in CMS reimbursement and customer procurement cycles suggest negative sentiment. The Q&A section reveals unclear management responses, further fueling uncertainty. These factors, coupled with a lack of strong positive catalysts, indicate a likely negative stock price movement over the next two weeks.
Ekso Bionics Holdings, Inc. (EKSO) Q2 2024 Earnings Call Summary
Positive
2024-07-30
The earnings call summary shows strong financial performance with improved gross margins and reduced net losses. The Q&A section indicates optimism about future revenue from CMS reimbursement, although specific delivery data was not disclosed. Strategic focus on IDNs and international expansion supports growth. Despite regulatory and competitive risks, the overall sentiment is positive, with a 6.4% sales increase and improved cash flow management. The absence of a share buyback program slightly tempers enthusiasm, but the positive momentum and optimistic guidance suggest a stock price increase of 2% to 8%.

FAQ

arrow icon

What were the key highlights of EKSO’s latest earnings report for FY2025Q2?

EKSO reported its FY2025Q2 earnings on 2025-07-28, showcasing a revenue of 2.06M against an estimate of 4.31M, resulting in a -52.3% surprise. The EPS was -1.24, surpassing the expected -1.2 by -3.33% . The stock experienced a -27.37% price change on the earnings day and a -22.96% change over the next five days, reflecting market reactions to the results.
arrow icon

How did EKSO’s stock price react after the FY2025Q2 earnings release?

arrow icon

What are the revenue and EPS estimates for EKSO for 2025/Q3?

arrow icon

How does EKSO’s stock price correlate with earnings forecast revisions?

arrow icon

What should investors expect from EKSO’s next earnings report?

arrow icon

What is the sentiment in Ekso Bionics Holdings Inc (EKSO) Q2 2025 Earnings Call Summary?